Y. Abdullatif, Karima Y. Ahmed, Fatma M. El-Senosy, Rasha Mohammed Abd El-Aziz
{"title":"2型糖尿病患者血清网膜蛋白-1水平及其与肥胖的关系","authors":"Y. Abdullatif, Karima Y. Ahmed, Fatma M. El-Senosy, Rasha Mohammed Abd El-Aziz","doi":"10.4103/sjamf.sjamf_227_21","DOIUrl":null,"url":null,"abstract":"Background Diabetes mellitus (DM) is a complex metabolic disorder, and its rapid emergence worldwide has led to its classification as an epidemic. Aim To increase our knowledge about omentin-1 and its relation with type 2 DM, insulin resistance, and obesity. Patients and methods This study included 50 patients with type 2 DM, with an age range from 40 to 70 years, who were divided into two groups (25 obese and 25 nonobese), as well as 40 age group (20 obese and 20 nonobese)-matched patients, who formed the control group. Each group was subjected to full history taking and clinical examination (fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein-cholesterol, glycosylated hemoglobin, fasting insulin, and serum omentin-1 levels). Weight and height were measured. Homeostasis model assessment insulin resistance and BMI were calculated. Results The study showed a significant decrease in serum omentin-1 levels in type 2 diabetic patients in comparison with the control group. Serum omentin-1 levels inversely correlated with obesity, insulin resistance, and systolic blood pressure. Negative associations were found between serum omentin-1 level and fasting glucose, glycosylated hemoglobin, and fasting lipid levels. Conclusion Omentin-1 may be used as a biomarker for obesity and associated metabolic and vascular disorders.","PeriodicalId":22975,"journal":{"name":"The Scientific Journal of Al-Azhar Medical Faculty, Girls","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum omentin-1 levels in type II diabetes and its relationship with obesity\",\"authors\":\"Y. Abdullatif, Karima Y. Ahmed, Fatma M. El-Senosy, Rasha Mohammed Abd El-Aziz\",\"doi\":\"10.4103/sjamf.sjamf_227_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Diabetes mellitus (DM) is a complex metabolic disorder, and its rapid emergence worldwide has led to its classification as an epidemic. Aim To increase our knowledge about omentin-1 and its relation with type 2 DM, insulin resistance, and obesity. Patients and methods This study included 50 patients with type 2 DM, with an age range from 40 to 70 years, who were divided into two groups (25 obese and 25 nonobese), as well as 40 age group (20 obese and 20 nonobese)-matched patients, who formed the control group. Each group was subjected to full history taking and clinical examination (fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein-cholesterol, glycosylated hemoglobin, fasting insulin, and serum omentin-1 levels). Weight and height were measured. Homeostasis model assessment insulin resistance and BMI were calculated. Results The study showed a significant decrease in serum omentin-1 levels in type 2 diabetic patients in comparison with the control group. Serum omentin-1 levels inversely correlated with obesity, insulin resistance, and systolic blood pressure. Negative associations were found between serum omentin-1 level and fasting glucose, glycosylated hemoglobin, and fasting lipid levels. Conclusion Omentin-1 may be used as a biomarker for obesity and associated metabolic and vascular disorders.\",\"PeriodicalId\":22975,\"journal\":{\"name\":\"The Scientific Journal of Al-Azhar Medical Faculty, Girls\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Scientific Journal of Al-Azhar Medical Faculty, Girls\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/sjamf.sjamf_227_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Scientific Journal of Al-Azhar Medical Faculty, Girls","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjamf.sjamf_227_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Serum omentin-1 levels in type II diabetes and its relationship with obesity
Background Diabetes mellitus (DM) is a complex metabolic disorder, and its rapid emergence worldwide has led to its classification as an epidemic. Aim To increase our knowledge about omentin-1 and its relation with type 2 DM, insulin resistance, and obesity. Patients and methods This study included 50 patients with type 2 DM, with an age range from 40 to 70 years, who were divided into two groups (25 obese and 25 nonobese), as well as 40 age group (20 obese and 20 nonobese)-matched patients, who formed the control group. Each group was subjected to full history taking and clinical examination (fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein-cholesterol, glycosylated hemoglobin, fasting insulin, and serum omentin-1 levels). Weight and height were measured. Homeostasis model assessment insulin resistance and BMI were calculated. Results The study showed a significant decrease in serum omentin-1 levels in type 2 diabetic patients in comparison with the control group. Serum omentin-1 levels inversely correlated with obesity, insulin resistance, and systolic blood pressure. Negative associations were found between serum omentin-1 level and fasting glucose, glycosylated hemoglobin, and fasting lipid levels. Conclusion Omentin-1 may be used as a biomarker for obesity and associated metabolic and vascular disorders.